All authors read and approved the final manuscript.”
“Introduction ARDS (Acute Respiratory selleckchem Distress Syndrome) is a frequent complication after trauma. Although mortality rates has been reduced over the last decade by improved treatment strategies and modalities, morbidity rates remain high, as the incidence of ARDS has only slightly decreased [1]. Several risk factors have been identified for the development of ARDS, such as

intramedullary osteosynthesis/nailing (IMN) of a femoral fracture, massive blood transfusion and thoracic injury [2]. When IMN is performed in the presence of these risk factors, the incidence of ARDS can be over 40%[3, 4]. In this case, IMN is seen as a second hit. Systemic inflammation is key in the development of ARDS. The amplitude of this systemic response is often measured by plasma IL-6 levels. However, systemic activation of the cellular innate immune system is essential in the development of ARDS [5]. When extravasation of polymorphonuclear granulocytes (i.e. PMNs or neutrophils) is blocked or animals are depleted of PMNs, no ARDS occurs after a sufficient insult [6]. In addition, in patients

with sepsis, circulating HLA-DR negative monocytes SRT1720 ic50 were identified, which point at a pro-inflammatory profile, as described previously. These cells are thought to contribute to additional tissue damage [7]. The role of these cells during IMN has not been investigated yet. This etiological study was designed to test the hypothesis whether IMN contributes to a more pronounced systemic inflammation, characterized by a change phenotype of cells of the innate immune system. This hypothesis was tested in 2 subgroups of patients with different injury severity (isolated femur fracture and femur fracture in multitrauma). Patients and methods Patients Forty-five trauma patients

were included in this study. They were admitted to the Department of Traumatology, University Medical Center Utrecht with a fracture of the femur, which required primary or secondary intramedullary PFKL nailing. Exclusion criteria were age < 16 years or > 80 years and patients with an altered immunological status (e.g. use of corticosteroids or chemotherapy). The local ethical committee approved the study and written informed consent was obtained from all patients or their spouses in accordance to the protocol. Clinical parameters and sampling The Injury Severity Score and APACHE II Score were calculated on admission. During admission the occurrence of Tipifarnib datasheet pulmonary complications (i.e.